Impact on Outcomes of Changing Treatment Guideline Recommendations for Stroke Prevention in Atrial Fibrillation: A Nationwide Cohort Study

Mayo Clinic Proceedings

Volumn 91, Issue 5, 2016, Pages 567-574

  Chao, Tze Fan ^a,b   Liu, Chia Jen ^a,b   Tuan, Ta Chuan ^a,b   Wang, Kang Ling ^a,b   Lin, Yenn Jiang ^a,b   Chang, Shih Lin ^a,b   Lo, Li Wei ^a,b   Hu, Yu Feng ^a,b   Chen, Tzeng Ji ^a   Chiang, Chern En ^a,b   Hsieh, Ming Hsiung ^c   Lip, Gregory Y H ^d   Chen, Shih Ann ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ADULT; AGE; AGED; ARTICLE; ATRIAL FIBRILLATION; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE ASSESSMENT; CEREBROVASCULAR ACCIDENT; CHA2DS2 VASC SCORE; CHADS2 SCORE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRACTICE GUIDELINE; SEX; TAIWAN; VASCULAR DISEASE; AGE DISTRIBUTION; CHEMICALLY INDUCED; COMORBIDITY; COMPLICATION; HEART FAILURE; INSURANCE; INTRACRANIAL HEMORRHAGES; ORAL DRUG ADMINISTRATION; PROCEDURES; RISK ASSESSMENT; SEX RATIO; STANDARDS; STATISTICS AND NUMERICAL DATA; STROKE; TREATMENT OUTCOME; VASCULAR DISEASES;

ADMINISTRATION, ORAL; AGE DISTRIBUTION; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; COMORBIDITY; DIABETES MELLITUS; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; INSURANCE CLAIM REVIEW; INTRACRANIAL HEMORRHAGES; MALE; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; SEX DISTRIBUTION; STROKE; TAIWAN; VASCULAR DISEASES; WARFARIN;

EID: 84966600773     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2016.03.007     Document Type: Article

References (23)

1. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 8 1991 983 988
2. L.S. Wann, A.B. Curtis, C.T. January, and et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 123 1 2011 104 123 Erratum in Circulation. 2011;124(5):e173
3. C.T. January, L.S. Wann, J.S. Alpert, et al. ACC/AHA Task Force Members 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society Circulation 130 23 2014 2071 2104 Erratum in Circulation. 2014;130(23):e270-e271
4. T.F. Chao, Y.C. Huang, C.J. Liu, and et al. Acute myocardial infarction in patients with atrial fibrillation with a CHA2DS2-VASc score of 0 or 1: a nationwide cohort study Heart Rhythm 11 11 2014 1941 1947
5. T.F. Chao, C.J. Liu, K.L. Wang, and et al. Using the CHA2DS2-VASc score for refining stroke risk stratification in 'low-risk' Asian patients with atrial fibrillation J Am Coll Cardiol 64 16 2014 1658 1665
6. T.F. Chao, C.J. Liu, K.L. Wang, and et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol 65 7 2015 635 642
7. T.F. Chao, C.J. Liu, S.J. Chen, and et al. Does digoxin increase the risk of ischemic stroke and mortality in atrial fibrillation? A nationwide population-based cohort study Can J Cardiol 30 10 2014 1190 1195
8. L.J. Lin, M.H. Cheng, C.H. Lee, D.C. Wung, C.L. Cheng, and Y.H. Kao Yang Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation-a nationwide descriptive study in Taiwan Clin Ther 30 9 2008 1726 1736
9. C.H. Chang, Y.C. Lee, C.T. Tsai, and et al. Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease Atherosclerosis 232 1 2014 224 230
10. B.F. Gage, A.D. Waterman, W. Shannon, M. Boechler, M.W. Rich, and M.J. Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 22 2001 2864 2870
11. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2 2010 263 272
12. A.J. Camm, G.Y. Lip, R. De Caterina, et al. ESC Committee for Practice Guidelines (CPG) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur Heart J 33 21 2012 2719 2747 Erratum in: Eur Heart J. 2013;34(10):790. Eur Heart J. 2013;34(36):2850-2851
13. C.T. January, L.S. Wann, J.S. Alpert, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society J Am Coll Cardiol 64 21 2014 e1 e76 Erratum in: J Am Coll Cardiol. 2014;64(21):2305-2307
14. I.M. Ogilvie, N. Newton, S.A. Welner, W. Cowell, and G.Y. Lip Underuse of oral anticoagulants in atrial fibrillation: a systematic review Am J Med 123 7 2010 638 645.e634
15. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 12 2007 857 867
16. C.W. Siu, G.Y. Lip, K.F. Lam, and H.F. Tse Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong Heart Rhythm 11 8 2014 1401 1408
17. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, et al. RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 12 2009 1139 1151 Erratum in: N Engl J Med. 2010;363(19):1877
18. A.M. Gallagher, E. Setakis, J.M. Plumb, A. Clemens, and T.P. van Staa Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients Thromb Haemost 106 5 2011 968 977
19. P. Gallego, V. Roldan, F. Marin, and et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation Thromb Haemost 110 6 2013 1189 1198
20. R.G. Hart, L.A. Pearce, R.M. Rothbart, J.H. McAnulty, R.W. Asinger, and J.L. Halperin Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators J Am Coll Cardiol 35 1 2000 183 187
21. S.H. Hohnloser, D. Pajitnev, J. Pogue, et al. ACTIVE W Investigators Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy J Am Coll Cardiol 50 22 2007 2156 2161
22. C.L. Cheng, Y.H. Kao, S.J. Lin, C.H. Lee, and M.L. Lai Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan Pharmacoepidemiol Drug Saf 20 3 2011 236 242
23. C.Y. Hsieh, C.H. Chen, C.Y. Li, and M.L. Lai Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database J Formos Med Assoc 114 3 2015 254 259